Patients
WorldHeart's pioneering first-generation Novacor LVAS has been clinically used since 1984, having served more than 1800 patients in North America, Europe and Japan. In 2008, its sale was discontinued worldwide. Additionally, WorldHeart's Levacor® VAD was implanted in 15 subjects during a Bridge-to-Transplant clinical study, which was discontinued in July 2011. Three subjects continue to be supported by the device.
Human Trials for the MiFlow™ and PediaFlow® VADs have not started.
If you have questions regarding clinical matters in North America or Europe, please contact:
- North American Clinical Inquiries: clinical@worldheart.com
- Europe Information: europeinfo@worldheart.com
Note: The information contained within this web site is not intended to substitute for professional advice from doctors or medical practitioners. Rather, it is a resource to improve understanding of heart failure and is not intended to substitute for clinical input.
Fast Facts
According to the United Network for Organ Sharing:
-
There were 2,350 heart transplants performed in the United States in 2009.
According to the American Heart Association:
-
Heart failure affects nearly five million Americans annually of all ages and is responsible for more hospitalizations than all forms of cancer combined.
According to the Heart Failure Society:
-
An estimated 400,000 to 700,000 new cases of heart failure are diagnosed each year and the number of deaths in the United States from this condition has more than doubled since 1979, averaging 250,000 annually.
Stay Informed
-
For an easy to read and informative description of various types of heart problems and disease and their causes, we recommend this report from the American Heart Association: